METROPOLIS - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.3
| Stock Code | METROPOLIS | Market Cap | 9,829 Cr. | Current Price | 1,895 ₹ | High / Low | 2,263 ₹ |
| Stock P/E | 73.6 | Book Value | 256 ₹ | Dividend Yield | 0.21 % | ROCE | 13.4 % |
| ROE | 10.5 % | Face Value | 2.00 ₹ | DMA 50 | 1,912 ₹ | DMA 200 | 1,921 ₹ |
| Chg in FII Hold | -0.84 % | Chg in DII Hold | 1.63 % | PAT Qtr | 46.6 Cr. | PAT Prev Qtr | 35.6 Cr. |
| RSI | 51.4 | MACD | -11.8 | Volume | 43,682 | Avg Vol 1Wk | 41,037 |
| Low price | 1,315 ₹ | High price | 2,263 ₹ | PEG Ratio | -5.27 | Debt to equity | 0.11 |
| 52w Index | 61.2 % | Qtr Profit Var | 10.3 % | EPS | 25.8 ₹ | Industry PE | 35.2 |
📊 Metropolis Healthcare (METROPOLIS) shows a cautious outlook for swing trading. The stock trades at ₹1,895, slightly below both its 50 DMA (₹1,912) and 200 DMA (₹1,921), reflecting short-term weakness. RSI at 51.4 indicates neutral momentum, while MACD at -11.8 signals mild bearishness. Valuation is stretched with a P/E of 73.6 compared to industry average of 35.2, and PEG ratio of -5.27 highlights poor earnings growth relative to valuation. Fundamentals remain moderate with ROE at 10.5% and ROCE at 13.4%. EPS of ₹25.8 and sequential PAT growth (+10.3%) provide positives, while institutional activity shows mixed signals with FII selling and DII buying.
✅ Optimal Entry Price: Around ₹1,860–1,880 (near support zone, slightly below current price).
🚪 Exit Strategy (if already holding): Consider exit near ₹1,950–2,000 (resistance zone close to 200 DMA). If price falls below ₹1,850, apply stop-loss to protect capital.
Positive
- 📈 Sequential PAT growth (₹46.6 Cr. vs ₹35.6 Cr.).
- 💹 ROE (10.5%) and ROCE (13.4%) show moderate efficiency.
- 📊 EPS of ₹25.8 supports valuation stability.
- 🏦 DII holdings increased (+1.63%).
- ⚡ Low debt-to-equity ratio (0.11).
Limitation
- ⚠️ Very high P/E (73.6 vs industry 35.2).
- 📉 PEG ratio (-5.27) indicates poor earnings growth.
- 📉 Trading below both 50 DMA and 200 DMA.
- 📉 Dividend yield is very low (0.21%).
Company Negative News
- 📉 FII holdings decreased (-0.84%).
- ⚠️ Valuation premium compared to peers.
Company Positive News
- 📈 PAT growth (+10.3% QoQ) shows operational improvement.
- 🏦 DII accumulation signals domestic investor confidence.
Industry
- 🏥 Diagnostics & healthcare sector average PE is 35.2, Metropolis trades at a steep premium (73.6).
- 📊 Sector demand remains resilient, supported by rising healthcare needs.
Conclusion
⚖️ Metropolis Healthcare is a moderately weak candidate for swing trading due to stretched valuation, bearish technicals, and FII selling. Entry near ₹1,860–1,880 offers limited risk-reward, while exits should be targeted near ₹1,950–2,000. Strong PAT growth, EPS support, and DII buying provide positives, but traders should remain cautious and apply strict stop-loss discipline below ₹1,850.